Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q3

9776.TEDINET S100Q4U9
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥15.3bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥19.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥14.3bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥817m2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥1.1bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥972m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.1bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥891m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥1.0bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥493m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥662m2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥578m2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥660m2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥16.9bnat 2022-12-31Cons.Assets
Total assets¥16.1bnat 2022-03-31Cons.Assets
Total assets¥15.5bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥6.1bnat 2022-12-31Cons.Liabilities
Total liabilities¥5.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥10.8bnat 2022-12-31Cons.Net assets
Net assets / equity¥10.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥10.0bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥4.1bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥3.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥147.852022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥70.532022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥306.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥193.962021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.832021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio62.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.2%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥75m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥73m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥3m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31¥49m
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥532m
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥601m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.2bn
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥726m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥495m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥8m
—segment totalrevenue2022-04-01 → 2022-12-31¥15.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥15.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥495m
—segment totalsegment profit2022-04-01 → 2022-12-31¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥15.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥498m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥80m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥79m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥723,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31¥55m
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥5.5bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥5.5bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥741m
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥7.9bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥7.9bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥642m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥724m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥994m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥12m
—segment totalrevenue2021-04-01 → 2021-12-31¥15.2bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥14.2bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥994m
—segment totalsegment profit2021-04-01 → 2021-12-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥14.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥995m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 387
ItemContextValueUnit
Net defined benefit liabilityPrior1YearInstant16107000JPY
Net defined benefit liabilityCurrentQuarterInstant17654000JPY
Long term accounts payable otherPrior1YearInstant97363000JPY
Long term accounts payable otherCurrentQuarterInstant91890000JPY
Other nclPrior1YearInstant6053000JPY
Other nclCurrentQuarterInstant20483000JPY
Noncurrent liabilitiesPrior1YearInstant2529694000JPY
Noncurrent liabilitiesCurrentQuarterInstant2369236000JPY
LiabilitiesPrior1YearInstant5811490000JPY
LiabilitiesCurrentQuarterInstant6078314000JPY
Capital stockPrior1YearInstant983350000JPY
Capital stockCurrentQuarterInstant983350000JPY
Capital surplusPrior1YearInstant1015270000JPY
Capital surplusCurrentQuarterInstant1015270000JPY
Retained earningsPrior1YearInstant8812690000JPY
Retained earningsCurrentQuarterInstant9228753000JPY
Treasury stockPrior1YearInstant-728236000JPY
Treasury stockCurrentQuarterInstant-757451000JPY
Shareholders equityPrior1YearInstant10083073000JPY
Shareholders equityCurrentQuarterInstant10469921000JPY
Valuation difference on available for sale securitiesPrior1YearInstant31227000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant36164000JPY
Valuation and translation adjustmentsPrior1YearInstant31227000JPY
Valuation and translation adjustmentsCurrentQuarterInstant36164000JPY
Non controlling interestsPrior1YearInstant223659000JPY
Non controlling interestsCurrentQuarterInstant308891000JPY
Net assetsPrior1YearInstant10337959000JPY
Net assetsCurrentQuarterInstant10814977000JPY
Liabilities and net assetsPrior1YearInstant16149449000JPY
Liabilities and net assetsCurrentQuarterInstant16893292000JPY
Net salesPrior1YTDDuration14285788000JPY
Net salesCurrentYTDDuration15250105000JPY
Cost of salesPrior1YTDDuration9558379000JPY
Cost of salesCurrentYTDDuration10426960000JPY
Gross profitPrior1YTDDuration4727408000JPY
Gross profitCurrentYTDDuration4823144000JPY
Selling general and administrative expensesPrior1YTDDuration3641047000JPY
Selling general and administrative expensesCurrentYTDDuration4006180000JPY
Operating incomePrior1YTDDuration1086360000JPY
Operating incomeCurrentYTDDuration816964000JPY
Interest income noiPrior1YTDDuration179000JPY
Interest income noiCurrentYTDDuration132000JPY
Dividends income noiPrior1YTDDuration5482000JPY
Dividends income noiCurrentYTDDuration5082000JPY
Rent income noiPrior1YTDDuration33592000JPY
Rent income noiCurrentYTDDuration30659000JPY
Subsidy income noi bountyPrior1YTDDuration50435000JPY
Subsidy income noi bountyCurrentYTDDuration146072000JPY
Other noiPrior1YTDDuration11704000JPY
Other noiCurrentYTDDuration19327000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass